Xanthine Oxidase
XO
Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.
Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.
All Product Categories
-
Xanthine Oxidase Related Products (160)
Related Products (160)
-
Antibodies (1)
-
HDAC-IN-79
0 ImagesCat. No.: HY-162910HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition.
-
H-Tyr-Phe-OH-13C9,15N TFA
0 ImagesCat. No.: HY-W011258BSSynonyms: L-Tyrosyl-L-phenylalanine-13C9,15N TFAH-Tyr-Phe-OH-13C9,15N ( (L-Tyrosyl-L-phenylalanine-13C9,15N)) TFA is the 13C- and 15N-labeled H-Tyr-Phe-OH (HY-W011258). H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells.
-
2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite
0 Images2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
-
Xanthine oxidase-IN-7
0 ImagesCat. No.: HY-146273CAS No.: 2411698-59-2Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout.
-
Xanthine oxidoreductase-IN-5
0 ImagesXanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia.
-
Xanthine oxidase-IN-11
0 ImagesCat. No.: HY-150257AXanthine oxidase-IN-11 (XO8 analog) is an xanthine oxidase (XO) inhibitor.
-
Xanthine oxidoreductase-IN-2
0 ImagesCat. No.: HY-146297CAS No.: 2396612-45-4Xanthine oxidoreductase-IN-2 (Compound IVa) is a xanthine oxidoreductase (XOR) inhibitor with the IC50 of 7.2 nM. Xanthine oxidoreductase-IN-2 shows hypouricemic effects in mice.
-
NARS-3′
0 ImagesCat. No.: HY-174318CAS No.: 2702589-46-4NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC50 of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.
-
2-Chloro-2'-deoxy-6-O-methylinosine
0 ImagesCat. No.: HY-154393CAS No.: 146196-07-82-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
-
Topiroxostat-d4
0 ImagesCat. No.: HY-14874SCAS No.: 2732868-49-2Synonyms: FYX-051-d4Topiroxostat-d4 is deuterium labeled Topiroxostat. Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment.
-
Xanthine oxidase-IN-13
0 ImagesCat. No.: HY-161455Xanthine oxidase-IN-13 (Compound 10) is a selective xanthine oxidase inhibitor (IC50: 149.56 μM for bovine xanthine oxidase). Xanthine oxidase-IN-13 can be used for research of inflammatory arthritis.
-
Xanthine oxidase-IN-23
0 ImagesCat. No.: HY-182000CAS No.: 3055112-52-9Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia.
-
Antioxidant agent-13
0 ImagesCat. No.: HY-155123CAS No.: 2966778-87-8Antioxidant agent-13 (Compound 5f) is an antioxidant agent. Antioxidant agent-13 inhibits DPPH and FRAP with IC50s of 80.33 and 85.69 μM. Antioxidant agent-13 also inhibits LOX and XO enzymes with IC50s of 16.85 and 23.01 μM.
-
Xanthine oxidase-IN-16
0 ImagesCat. No.: HY-162961Xanthine oxidase-IN-16 is potent and orally active xanthine oxidase (XO) inhibitor with an IC50 of 102 nM. Xanthine oxidase-IN-16 shows significant efficacy in hyperuricemia rats.
-
Cholesterol oxidase, PEG Modified
0 ImagesCat. No.: HY-P2848ESynonyms: ChOx, PEG ModifiedCholesterol oxidase, PEG Modified (ChOx, PEG Modified) (EC 1.1.3.6) is a cholesterol oxidase identified from bacterial sources. Cholesterol oxidase, PEG Modified catalyzes the oxidation of cholesterol to 4-cholesten-3-one, while simultaneously reducing oxygen to hydrogen peroxide. Cholesterol oxidase, PEG Modified retains its enzymatic activity and exhibits improved catalytic efficiency upon immobilization. Cholesterol oxidase, PEG Modified is applicable for cholesterol detection, steroid biotransformation, and research on tuberculosis-related diseases.
-
2,6-Dihydroxyacetophenone (Standard)
0 Images2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia.
-
Xanthine oxidase-IN-19
0 ImagesCat. No.: HY-179030CAS No.: 3055301-22-6Xanthine oxidase-IN-19 (Compound 13i) is an orally effective inhibitor of xanthine oxidase (XO), with an IC50 of 0.2 μM. Xanthine oxidase-IN-19 can significantly reduce serum uric acid levels in acute hyperuricemia rat models. Xanthine oxidase-IN-19 can be used for the study of acute hyperuricemia.
-
2-Chloro-6-methoxypurine riboside
0 ImagesCat. No.: HY-W039271CAS No.: 15465-92-6Synonyms: 2-Chloro-6-O-methyl-inosine2-Chloro-6-methoxypurine riboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia.
-
Baicalein hydrate
0 ImagesCat. No.: HY-N0196ACAS No.: 352000-07-8Synonyms: 5,6,7-Trihydroxyflavone hydrateBaicalein hydrate (ALA; C18:3 (9Z,12Z,15Z); C18:3 n-3) is a xanthine oxidase inhibitor with an IC50 value of 3.12 μM.
